{"title":"Exploring the unexplored: identifying knowledge gaps in novel pharmacological treatments for diabetic retinopathy","authors":"Amin Sharifan, Sobha Sivaprasad","doi":"10.1038/s41433-024-03349-x","DOIUrl":null,"url":null,"abstract":"<p>Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].</p><p>Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].</p>","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03349-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetic retinopathy is a serious condition that can lead to diabetic macular oedema or vision loss. In 2020, approximately 103·12 million diabetic patients worldwide were affected by retinopathy. This number is projected to increase to 129·84 million and 160·50 million in 2030 and 2045, respectively. Regions most impacted by diabetic retinopathy are anticipated to be the Western Pacific, Middle East and North Africa, and North America and Caribbean [1].
Whilst anti-vascular endothelial growth factor treatment has improved visual outcomes for patients with diabetic retinopathy, reports indicate that some do not achieve complete resolution of diabetic macular oedema, and most require multiple injections and prolonged treatments. These limitations have spurred interest in novel agents with more effective control of diabetic retinopathy [2].
期刊介绍：
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
